INT202595

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 0.50
Pain Relevance 0.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

structural molecule activity (Krt36)
Anatomy Link Frequency
hair 1
Krt36 (Mus musculus)
Pain Link Frequency Relevance Heat
withdrawal 4 79.52 Quite High
Pain 54 69.48 Quite High
alcohol 2 45.28 Quite Low
anesthesia 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adhesions 2 90.36 High High
Clinical Trials And Case Reports 8 88.72 High High
Pain 54 69.48 Quite High
Aging 12 67.56 Quite High
Targeted Disruption 25 49.24 Quite Low
Injury 3 47.84 Quite Low
Depression 4 42.72 Quite Low
Alopecia 34 5.00 Very Low Very Low Very Low
Hypertension 8 5.00 Very Low Very Low Very Low
Obesity 8 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For example, TERT strongly activated expression of hair keratins, such as Krt31 through Krt36.
Gene_expression (expression) of Krt36 in hair
1) Confidence 0.56 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2211538 Disease Relevance 0.09 Pain Relevance 0.04
Development and testing of HRA-E
Gene_expression (Development) of HRA-E
2) Confidence 0.35 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0.09 Pain Relevance 0
However, despite these advantages, there are factors limiting the use of the HRA-E in Europe: first it had not been developed for use in a multilingual environment, second its feasibility and performance had not been tested outside the North American environment, and third, the HRA-E is outdated because new scientific evidence has accumulated since its development in 1997.
Gene_expression (use) of HRA-E
3) Confidence 0.35 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0 Pain Relevance 0
Feed-back to the HRA-O questionnaire
Gene_expression (questionnaire) of HRA-O
4) Confidence 0.30 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0 Pain Relevance 0
Response to HRA-O questionnaire
Gene_expression (questionnaire) of HRA-O
5) Confidence 0.30 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0 Pain Relevance 0
Testing of HRA-O-version-2 (HRA-O-2)
Gene_expression (Testing) of HRA-O
6) Confidence 0.30 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0.13 Pain Relevance 0.13
Testing of HRA-O-version-2 (HRA-O-2)
Gene_expression (Testing) of HRA-O
7) Confidence 0.30 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0.13 Pain Relevance 0.13
JH and JB was responsible for HRA-O development in the United States.
Gene_expression (development) of HRA-O
8) Confidence 0.30 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0 Pain Relevance 0
As a result, HRA-O-4 was produced in an American English, U.K.
Gene_expression (produced) of HRA-O
9) Confidence 0.27 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783663 Disease Relevance 0.07 Pain Relevance 0
GPs (and practice nurses in London) were encouraged to reinforce the HRA-O during usual encounters with their patients.
Gene_expression (reinforce) of HRA-O
10) Confidence 0.13 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783855 Disease Relevance 0 Pain Relevance 0
Use of HRA-O instrument
Gene_expression (instrument) of HRA-O
11) Confidence 0.13 Published 2007 Journal BMC Med Res Methodol Section Body Doc Link PMC1783855 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox